(NASDAQ:TLX), SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is January 9, 2026. The lawsuit follows a series of regulatory setbacks and […]

NEW YORK, NY / ACCESS Newswire / December 8, 2025 / – SueWallSt: Class Action Filed Against Marex Group plc – Contact Levi & Korsinsky A Class Action lawsuit was filed on behalf of investors who lost money as a result of alleged securities fraud between May 16, 2024 and August 5, 2025. If you

Telix (TLX) Facing Securities Class Action Lawsuit Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain – Hagens Berman Partner Reed Kathrein Scrutinizes Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — National shareholder

Consistent and robust efficacy demonstrated across bleed types, locations, and dose cohorts The weekly dosing cohort achieved an estimated 87% reduction in annualized treated bleeding rate (ATBR) Results validate potential as the first prophylactic therapy to address the heavy physical and psychosocial burden of Glanzmann thrombasthenia; Phase 3 registration study planned for 2026 Hemab Therapeutics,

(NASDAQ:TERN), 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with longer duration of treatment Company to host investor update call today at 4:30pm ET FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Terns

Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting GlobeNewswire December 08, 2025 64% MMR achievement by 24 weeks across all efficacy evaluable patients 75% MMR achievement by 24 weeks in efficacy evaluable patients at doses >320mg QD Encouraging safety/tolerability profile maintained with

NEW YORK, NY / ACCESS Newswire / December 8, 2025 / – SueWallSt: Class Action Filed Against Primo Brands Corporation / Primo Water Corporation – Contact Levi & Korsinsky A Class Action lawsuit was filed on behalf of investors who lost money as a result of alleged securities fraud between June 17, 2024 and November

(NYSE:KMX), SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman reminds investors that the deadline to move the Court for appointment as lead plaintiff in the securities class action lawsuit against CarMax, Inc. (NYSE: KMX) is January 2, 2026. The lawsuit alleges that CarMax and its executives provided materially

KMX Investor Alert: Hagens Berman Notifies Investors of Suit Over CarMax's Alleged “Temporary Demand Pull-Forward” and Loan Portfolio Risk Partner Reed Kathrein Scrutinizing Undisclosed Business Weakness Preceding Dual Stock Crashes Totaling Over 44% GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — National shareholder rights law firm Hagens Berman reminds investors that

NEW YORK, NY / ACCESS Newswire / December 8, 2025 / – SueWallSt: Class Action Filed Against Stride, Inc. – Contact Levi & Korsinsky A Class Action lawsuit was filed on behalf of investors who lost money as a result of alleged securities fraud between October 22, 2024 and October 28, 2025. If you suffered